GATC Biotech's GATCLiquid

GATC Biotech has released a new liquid biopsy offering for early-access clinical research and product development called GATCLiquid Technology Suite. Based on next-generation sequencing and GATC's proprietary analysis techniques, the suite is aimed at the detection of genomic alterations in circulating DNA for diagnostic purposes, such as identifying clinically actionable genomic alterations that influence tumor development or treatment outcomes.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.